Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetanus immune globulin
- Development stage
- Approved
- Lead developer
- Grifols
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Tetanus immune globulin is a human-derived polyclonal antibody preparation containing high titers of antibodies against the tetanus toxin. It provides immediate passive immunity by neutralizing unbound tetanus toxin in individuals at risk for or with suspected exposure to *Clostridium tetani*. The drug is used both for post-exposure prophylaxis in patients with wounds at high risk of developing tetanus (especially those not fully vaccinated) and as part of the treatment regimen for active tetanus infection, typically alongside antibiotics and muscle relaxants. Tetanus immune globulin does not confer long-term immunity; it offers short-term protection until the patient’s own immune system can respond to vaccination. The product is manufactured from pooled human plasma collected from donors immunized with tetanus toxoid[1][3][5][8].
- Brand names
- BaytetHyperTET S/D
- Other names
- tetanus antitoxinanti-tetanus immunoglobulin
Beyond the preview
Go deeper on Tetanus immune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tetanus immune globulin.